Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

NCT05576389 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Germline BRCA-mutated HER2-negative Breast Cancer

Interventions

DRUG: Camrelizumab+Fluzoparib

Sponsor

Peking University People's Hospital

Collaborators

[object Object]